AVALO THERAPEUTICS, INC. Cash Acquired from Acquisition
AVALO THERAPEUTICS, INC. (AVTX) reported Cash Acquired from Acquisition of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Cash
us-gaap:CashAcquiredFromAcquisition · last filed 2026-03-23
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for the quarter ending 2025-12-31 was $0.00.
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for the quarter ending 2025-09-30 was $0.00.
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for the quarter ending 2025-06-30 was $0.00.
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for fiscal 2024 was $356.00K.
- AVALO THERAPEUTICS, INC. cash acquired from acquisition for fiscal 2023 was $0.00.
| Period end | Cash Acquired from Acquisition 3 month | Cash Acquired from Acquisition 6 month | Cash Acquired from Acquisition 9 month | Cash Acquired from Acquisition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 derived: sum of 4 quarters · filed 2026-03-23 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 derived: sum of 4 quarters · filed 2026-03-23 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $356.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $356.00K 10-Q · filed 2025-11-06 | $356.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $356.00K 10-Q · filed 2025-08-07 | $356.00K derived: sum of 3 quarters · filed 2025-08-07 | $356.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $356.00K 10-Q · filed 2025-05-12 | $356.00K derived: sum of 2 quarters · filed 2025-05-12 | $356.00K derived: sum of 3 quarters · filed 2025-05-12 | $356.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-12 | $0.00 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |